SCHEMBL337707

SCHEMBL337707

CC(C)(C)OC(=O)[C@@H](N)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GSR P00390 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
GRIA4 P48058 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIK2 Q13002 1/20 0.52
GRIK3 Q13003 1/20 0.52
GRIN2B Q13224 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740146 1.00 CYP1A2 (0.52) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL561334 1.00 CYP1A2 (0.52) CYP1A2GRM8GRM6GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL3580142 0.98 CYP1A2 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL2124740 0.98 CYP1A2 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL2124734 0.98 CYP1A2 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL28096244 0.98 CYP1A2 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL15888382 0.90 GABRP (0.41) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL30439764 0.89 ENPEP (0.43) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL2218974 0.89 ENPEP (0.43) CYP1A2GRM8GRM6GRIN2DGRIN3B
Aminocaproic Acid SCHEMBL5709467 0.87 LMNA (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289842-A1 Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates AMGEN INC. 2025-09-18 US claimed
CN-119350469-B Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method 杭州诺澳生物医药科技有限公司 2025-05-23 CN claimed
WO-2025094036-A1 A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE PIRAMAL PHARMA LIMITED (IN) 2025-05-08 WO claimed
EP-4532531-A1 PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 ScinoPharm Taiwan, Ltd. (TW) 2025-04-09 EP claimed
CN-119708196-A Tenipout peptide synthesis method 深圳翰宇药业股份有限公司 2025-03-28 CN claimed
WO-2025052429-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF TIRZEPATIDE NEULAND LABORATORIES LIMITED (IN) 2025-03-13 WO claimed
EP-4519278-A1 PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES Amgen Inc. (US) 2025-03-12 EP claimed
CN-119139157-B Hair loss preventing and caring component, preparation method thereof and shampoo 广州市圣莎拉化妆品有限公司 2025-03-07 CN claimed
CN-119562958-A Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof 安进公司 2025-03-04 CN claimed
CN-118772035-B Method for efficiently preparing fatty diacid derivative and application thereof 合肥亿帆生物制药有限公司 2025-02-28 CN claimed
CN-101955515-A Progesterone releasing hormone-methotrexate compound and pharmaceutical application thereof UNIV CHONGQING MEDICAL 2011-01-26 CN claimed
EP-0737197-B1 AMINO ALKANOIC ESTERS OF RAPAMYCIN AMERICAN HOME PROD (US) 2002-05-08 EP claimed
EP-1171149-A1 INHIBITION OF PROTEASOME FUNCTION INDUCES PROGRAMMED CELL DEATH IN ENDOTHELIAL CELLS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2002-01-16 EP claimed
EP-1053750-A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis) Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2000-11-22 EP claimed
WO-2000064467-A1 INHIBITION OF PROTEASOME FUNCTION INDUCES PROGRAMMED CELL DEATH IN ENDOTHELIAL CELLS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2000-11-02 WO claimed
JP-H09507236-A 1997-07-22 JP claimed
EP-0737197-A1 AMINO ALKANOIC ESTERS OF RAPAMYCIN AMERICAN HOME PRODUCTS CORPORATION (US) 1996-10-16 EP claimed
WO-1995018133-A1 AMINO ALKANOIC ESTERS OF RAPAMYCIN AMERICAN HOME PRODUCTS CORPORATION (US) 1995-07-06 WO claimed
US-5389639-A Immunosuppressants AMERICAN HOME PRODUCTS COMPANY (US) 1995-02-14 US claimed
EP-0294294-A2 Amine derivatives of anthracycline antibiotics CYTOGEN CORPORATION (US) 1988-12-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289842-A1 Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates ENGASE, MAN2B2, GALNT2 CYP1A2 4771/4885GRM8 3513/4885GRM6 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.